|
Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
Sacramento Bee The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL™ (bupivacaine liposome injectable suspension), was approved for administration into the surgical site to produce ... |
Read the full story:
Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering - Sacramento Bee
You must log in to post a comment.